de-DEen-US
Skip to main content
Resources for psychedelic research and consciousness expansion (LSD derivatives)

Scientific Research

Significance and Potential of Psychedelics in Science

Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression

Abstract

Phase 2b dose-ranging trial (COMP360) in 233 participants with treatment-resistant depression. The 25 mg psilocybin group showed significantly greater reduction in MADRS depression score at week 3 compared to the 1 mg control group.

Keywords

psilocybintreatment-resistant depressionCOMP360phase 2bCOMPASS Pathways
Clinical Research